A Roche cancer drug that treats lung cancer with a certain genetic signature now has an additional FDA approval that expands the applications of the blockbuster product. The drug, Alecensa, is already ...
Comparative survival outcomes among histological subtypes of non-small cell lung cancer in the United States. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does ...
AstraZeneca AZN announced that the FDA expanded the label of its blockbuster cancer drug Imfinzi for a fourth indication in lung cancer. The FDA approved Imfinzi in combination with platinum-based ...
AstraZeneca AZN announced that the FDA has expanded the label of its cancer drug Datroway for a second indication — non-small cell lung cancer (NSCLC). The drug has been developed in partnership with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results